SMi EVENT – 9th Annual RNA Therapeutics Conference!

SMi Group announces the 9th Annual RNA Therapeutics Conference in London on February 21st – 22nd 2018.

RNA t[

As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.http://bit.ly/2xtvCH1

One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and evaluate with key industry leaders the lessons they’ve learnt whilst developing an RNA therapeutic.  The full speaker line-up and conference agenda is available at http://www.therapeutics-rna.com/bnths 

For more information visit the website at http://www.therapeutics-rna.com/bnths or contact the team on email: psolanki@smi-online.co.uk or call +44 (0) 207 827 6012

Journal: Current Pharmaceutical Design

EBook: Frontiers in RNAi

SMi EVENT – 20th annual Superbugs & Superdrugs conference!

Providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities, SMi presents the 20th annual Superbugs & Superdrugs conference which will return to Central London on 19th and 20th March 2018.

superbugs

The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders from Nemesis Bioscience, ABAC Therapeutics, Oppilotech, Gladius Pharmaceuticals, Pew Charitable Trusts, Blueberry Therapeutics, UNT Health Science Center, ContraFect, SCYNEXIS; and government bodies such as MHRA and DNDi. The full speaker line-up and conference agenda is available at http://www.superbugssuperdrugs.com/bentham

Relevant Journal: Anti-Infective Agents

Relevant EBook: Frontiers in Anti-Infective Drug Discovery

SMi EVENT – 2nd Annual 3D Cell Culture Conference!

SMi Group is thrilled to present the 2nd Annual 3D Cell Culture conference, taking place on 21st & 22nd February 2018 in London, UK.

200X200 cell culture

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK. 3D Cell Culture is rapidly growing with incredible potential for industrial application and a widespread reach that can be seen across many different fields, such as 3D bioprinting and microfluidics. The 2nd annual conference will explore these overlapping areas and will combine pioneering breakthroughs with scientific research to strengthen your commercial success. Join us for exclusive insight into key topics such as disease models, organoids, organ-on-a-chip technologies, Ipsc advances and CRISPR technology. Notable speakers on the agenda for 2018 will include experts from Aurelia Bioscience, ReInnervate Limited, Cell & Gene Therapy Catapult, Novartis Institutes for Biomedical Research, Kugelmeiers , Immunocore, GSK, UK Regenerative Medicine Platform, TissUse GmbH, Jellagen and more! The full speaker line-up and detailed agenda is available at http://www.3D-CellCulture.com/bentham

Relevant Journal: Current Biotechnology

Relevant EBook: Advances in Biotechnology

SMi EVENT – 12th annual Parallel Trade!

SMi Group is proud to announce the return of Europe’s only Parallel Trade conference. Back for the 12th year, Parallel Trade returns to London on 6th-7th February 2018.

parallel trade

Over the years, the European Single market has allowed for pharmaceuticals to be imported and exported freely between member states without the permission of the manufacturers. However, with the arrival of Brexit and guidelines to immanently enforce the Falsified Medicines Directive (FMD) by 2019, the market for pharmaceutical parallel trade is changing.

Join us as we discuss the latest changes to regulation, their implementation and major court cases in intellectual property influencing distribution practices. We will also be exploring the safety of patients in relation to the surge in pharmaceutical E-commerce and ways in which currency fluctuations are likely to disrupt the flow of drugs to certain countries in the EU and beyond.

With huge interest from leaders in the field, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Parallel Trade event. This year’s event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations from our confirmed Industry-leading speakers:

  • Antonio Mendonca Alves, CEO, Md Pharma Sa
  • Christopher Stothers, Partner, Arnold And Porter Kaye Scholer Llp
  • Darragh O’loughlin, Secretary General, Irish Pharmacy Union
  • Eric Noehrenberg, President, Noehrenberg International Policy Consulting
  • Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara
  • Farasat Bokhari, Senior Lecturer in Economics, Uea, University of East Anglia
  • Felipe Florez-Arango, Head of Finance, Europe, Shire
  • Frank Weissenfeldt, Senior Manager, Supplier Relations, Quintilesims
  • Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies
  • Ian Walker, Chairman, Epilepsy Action
  • Janice Haigh, VP Pricing & Market Access, Parexel
  • John Jolley, Managing Director, Pharmaconsult Global Ltd
  • Mikas Rimantas, Business Development Director, Lexano
  • Werner Berg, Partner, Baker & Mckenzie

Parallel Trade will address short term versus long term concerns of pharmaceutical manufacturers, regulators, parallel traders and patient associations.

The 2018 Parallel Trade conference will cover the important issues of:

  • Maintaining the integrity of the supply chain
  • Addressing recent developments concerning intellectual property and regulatory law
  • Forecasting currency fluctuations across the single market and the affect this might have on drug shortages, prices and patient accessibility
  • Exploring how Brexit will impact pharmaceutical trade and
    market access in Europe
  • Providing an insight into current anti-trust investigations from industry leaders and the consequences this could have on pharmaceutical parallel trade

For more information visit the website at www.pharma-microbiology.com/BENTHAM or contact the team on email: kwilliams@smi-online.co.uk or call +44 (0) 207 827 6012

Journal: Current Drug Safety 

EBook: Frontiers in Clinical Drug Research – Anti-Cancer Agents

SMi EVENT – 7th annual Pharmaceutical Microbiology!

SMi Group is thrilled to present the 7th annual Pharmaceutical Microbiology taking place on 22nd – 23rd January 2018 in London, UK.

200 x 200 copy

SMi’s 7th annual Pharmaceutical Microbiology UK conference will provide attendees essential indicators for Quality Assurance and Quality Control whilst presenting that latest information on protecting pharmaceutical and healthcare products from spoilage by microorganisms, and protecting patients and consumers.

This 2018 event will provide an in-depth overview of the function of the pharmaceutical microbiologist and what they need to know, from regulatory filing and GMP, to laboratory design and management, and risk assessment tools and techniques. These key aspects are discussed through a series of dedicated presentations, keynote sessions and workshops, with topics covering biofilms, validation, data analysis, bioburden, toxins, microbial identification, mycoplasma testing, and contamination control.

CHAIRS FOR 2018

  • Oliver Chancel, Sterility and Aseptic Process, Assurance Expert, Merial Sas
  • Andrew Bartko, Research Leader, Battelle Memorial Institute

Expert Speaker Line-Up Features:

  • Renate Rosengarten, Professor and Chair of Bacteriology and Hygiene, University of Veterinary Medicine Vienna
  • Ingo Spreitzer, Deputy Head Section Microbial Safety, Paul-Ehrlich Institute
  • Ruth Daniels, Senior Scientist Microbiology, Janssen
  • Jeremy Webb, Professor of Microbiology, Principal Investigator (Biofilms and Microbial Communities), University of Southampton
  • Shahram Lavasani, CEO & Founder, ImmuneBiotech

Exclusive highlights in 2018:

  • Hear about new mycoplasma testing methods to optimise contamination control
  • Gain insight from a regulatory perspective on ways to make testing methods compliant
  • Explore actual implementation of rapid microbial methods within a laboratory setting, that meet regulatory requirements
  • Gain an in-depth understanding of biofilms and why they pose such an issue in terms of drug development and delivery
  • Receive updates on the current research being done to circumvent the issues posed by biofilms

For more information visit the website at www.pharma-microbiology.com/BENTHAM or contact the team on email: kwilliams@smi-online.co.uk or call +44 (0) 207 827 6012

Journal: Current Pharmaceutical Biotechnology

EBook: Frontiers in Anti-Infective Drug Discovery 

 

SMi EVENT – 7th annual Orphan Drugs and Rare Diseases UK!

SMi Group is thrilled to present the 7th annual Orphan Drugs and Rare Diseases conference, taking place on 18th & 19th October 2017 in Central London, UK. This year’s theme will be focused towards discussing strategies for patient engagement, market access and gene therapies to enhance rare diseases and orphan drug research.

200 X 200 copykiuj

Aimed at an audience of senior scientists and oncology specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing.

Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts.

 

Exclusive highlights in 2017:

  • Learn about new therapies for different rare diseases, and how these can successfully be applied to other diseases with similar attributes
  • Hear what opportunities and challenges come with working on rare diseases, as well as the development of the world’s first rare disease centre for children
  • Expand your knowledge on patient collaboration and patient centric models with the stream on patient engagement, covering improvement strategies, patient-led trials, and much more
  • Gather further insight on drug approval and reimbursement with MAA, and how techniques for drug repurposing in the rare disease area can help treatment.

For more information visit the website at www.orphandrugs.co.uk/bentham or contact the team on email: kwilliams@smi-online.co.uk or call +44 (0) 207 827 6012

Journal: Current Medicinal Chemistry

EBook: Frontiers in Anti-Cancer Drug Discovery Volume 6

SMi EVENT – 6th annual Cancer Vaccines Conference 2017

SMi Group is thrilled to present the 6th annual Cancer Vaccines conference, taking place on 27th & 28th September 2017 in Central London, UK. Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies.

200 x 200 copy

Aimed at an audience of senior scientists and oncology specialists involved in targeted vaccines and drug research, Cancer Vaccines 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of cancer immunotherapy. The 6th annual show will capture expert insight by honing in on new pathways with novel vaccines and immunotherapies, drug formulations, personalised treatment, immune check-point inhibitors, plus more.

Join us this September for strategic direction on vaccine commercialisation and arm yourself with the key requirements and tools for successful vaccine development through informed guidance delivered by a top panel of speakers.

Exclusive highlights in 2017:

  • Exploring personalising cancer vaccines, characterising and applying the outside in approach in cancer vaccine development
  • Maximising the therapeutic potential of cancer vaccines in combination with immune checkpoint inhibitors
  • In depth case study examples of peptide, DNA, neoantigen and MHC based vaccine development
  • Assessing the use of preclinical data for cancer vaccines

For more information visit the website at www.cancervaccinesevent.com/bentham  or contact the team on email: kwilliams@smi-online.co.uk or call +44 (0) 207 827 6012

Journal: Current Cancer Drug Targets

EBook: Topics in Anti-Cancer Research Volume 4

SMi EVENT – Microbiology East Coast 2017

Drawing on from the huge success of SMi’s Pharmaceutical Microbiology event series, SMi is delighted to announce the launch of Pharmaceutical Microbiology East Coast. Being the eighth in its series, this event will take place in New Jersey, USA, on November 13th and 14th 2017.

200 x 200 copy.jpg

Aimed at Microbiologists, Quality Control and Quality Assurance Managers, Pharmaceutical Microbiology East Coast 2017 will address the best practices for rapid microbial and sterility testing and tackle the challenges of contamination control.

Pharmaceutical Microbiology East Coast has been produced with a vision of promoting the field of microbiology, and has been tailored to address the current issues and opportunities the industry faces every day. Topics of interest will include:

  • The role of microbiology in pharmaceutical stability programs
  • Deciphering the host-microbe interaction
  • Benefits of real-time monitoring of airborne viable microorganisms
  • Current expectations for a complete environmental monitoring program
  • Quality control strategy on low endotoxin recovery (LER)
  • Implementation of a global electronic intervention logging system

For more information visit the website at www.microbiologyeastcoast.com/bentham or contact the team on email: kwilliams@smi-online.co.uk or call +44 (0) 207 827 6012

Journal: Anti-Infective Agents 

EBook: Anti-Infective Drug Discovery Volume 3

SMi EVENT – Superbugs and Superdrugs USA 2017

Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group are thrilled to announce the return of Superbugs and Superdrugs USA which arrives to Iselin, New Jersey on November 13th & 14th 2017.

200X200-Superbugs

Antimicrobial resistance has sparked an urgency in the development of new drugs as the industry strives for novel solutions to fight infectious diseases. Innovation and collaboration is requested at every level making Superbugs & Superdrugs USA, the perfect platform to strengthen knowledge in key principles such as funding incentives and global strategy, whilst honing in on clinical developments in areas such as immunotherapy, toxoid based vaccines and anti-body drug conjugates. As methods move away from traditional small molecule antibiotics, this is critical time for AMR experts, government bodies and industry leaders, to come together and share ideas on the latest developments in treatment and prevention. Featured speakers include: Janssen, UNT Health Science Center, John Rex from CARB-X, BARDA, Pfizer, Merck, DemovaMed, Visterrra, Microbiotix more.

For more information visit the website at http://www.superbugs-usa.com/bentham or contact the team on email: events@smi-online.co.uk or call +44 (0)20 7827 6000

Journal: Anti-Infective Agents 

EBook: Frontiers in Anti-Infective Drug Discovery

SMi EVENT – In Vitro Diagnostics 2017

The third in its series, SMi is delighted to announce the return of In Vitro Diagnostics taking place in London on the 14th & 15th June 2017.

IVD 150x150 copy

Aimed at Managers/Heads and Directors of Regulatory Affairs, In Vitro Diagnostics, Clinical Affairs and Quality Assurance, IVDs 2017  will provide regulatory updates and key industry feedback from leading IVD manufacturers within this complex and ever-changing landscape.

Through a series of presentations from handpicked industry experts and Notified Bodies, the 2017 event will prepare attendees for the challenging times ahead and how to comply with regulatory requirements to ensure direct access to market ensuring the continued growing demand for use and innovation of IVDs over the next decade and beyond. Topics of discussion include: Latest updates on the IVD regulation, the changing role of notified bodies as well as the increase in requirements for clinical evidence.

For details or to register, visit the website at www.in-vitro-diagnostics.co.uk/benthamscience or contact the team at +44(0) 207827 6000, email kobanigba@smi-online.co.uk

Journal: Applied Clinical Research, Clinical Trials and Regulatory Affairs

EBook: The Role of New Technologies in Medical Microbiological Diagnosis and Research